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A B S T R A C T
Purpose: Levetiracetam has been reported to be well tolerated and effective in status epilepticus (SE)
refractory to benzodiazepine. Because of little preclinical or clinical data concerning the outcomes of LEV
in SE-induced neuronal death and vasogenic edema, we investigated the effect of LEV on SE-induced
injury in comparison to diazepam (DZP), and valproate (VPA).
Methods: Two hours after pilocarpine-induced SE, rats were given one of the following drugs; (1) DZP,
(2) LEV, (3) VPA, (4) DZP + LEV, (5) DZP + VPA, and (6) DZP + oxiracetam. Three–four days after SE,
neuronal damage and vasogenic edema were evaluated by Fluoro-Jade B (FJB) staining and serum-
protein extravasation, respectively.
Results: LEV (50 mg/kg) was effective to protect neuronal damage from SE in comparison to DZP and
VPA. LEV as an add-on drug with DZP could not alleviate neuronal damage as compared to LEV alone. VPA
(100 mg/kg) was effective to protect neuronal damage from SE, as compared to DZP. VPA as an add-on
drug with DZP reduced neuronal damage, as compared to DZP alone.
Conclusion: These ﬁndings suggest that LEV may negatively interact with DZP, and be more effective to
prevent SE-induced neuronal death as a ﬁrst line drug than as a second line therapy after BDZ treatment.
 2013 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at SciVerse ScienceDirect
Seizure
jou r nal h o mep age: w ww.els evier . co m/lo c ate /ys eiz1. Introduction
Status epilepticus (SE) is a medical emergency with signiﬁcant
mortality, which is deﬁned as continuous unremitting seizure
activity longer than 5 min.1 SE causes severe neuronal cell death
that may involve epileptogenesis and learning impairment.1 In
particular, the piriform cortex (PC) and the hippocampus are the
most susceptible brain regions vulnerable to SE insults.2 SE also
induces severe vasogenic edema in the PC accompanied by
neuronal and astroglial damages.2 In SE animal models for epilepsyAbbreviations: AED, antiepileptic drug; BZD, benzodiazepines; DZP, diazepam; FJB,
Fluoro-Jade B; LEV, levetiracetam; OXI, oxiracetam; PHT, phenytoin; PC, piriform
cortex; SE, status epilepticus; VPA, valproate.
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1059-1311/$ – see front matter  2013 British Epilepsy Association. Published by Else
http://dx.doi.org/10.1016/j.seizure.2013.02.005study, diazepam (DZP) is used to control seizure activity, since DZP
rapidly acts with high efﬁcacy rates against chemical (e.g.,
pilocarpine and kainic acid)-induced SE.2,3
In clinical practice, similarly, treatment of SE has not changed in
the last few decades. Currently, benzodiazepines (BZD) (lorazepam
or DZP) followed by phenytoin (PHT) are considered as ﬁrst line
treatment in the majority of the guidelines.4 However, this ﬁrst-
line therapy fails to control at least 35–45% of patients with SE.5 In
this case, valproate (VPA) has been used as a second-line agent.6
Agarwal et al. reported that PHT and VPA were surprisingly highly
effective (controlling SE in 88% and 84% of patients, respectively) in
patients of BZD refractory SE.7 More recently, levetiracetam (LEV)
is also used as second-line therapy for SE.8 LEV (2S-(oxo-1-
pyrrolidinyl)butanamide, Keppra1, UCB Pharma) is an antiepilep-
tic drug (AED) showing both anticonvulsant and antiepileptogenic
effects in kindling models and neuroprotective effects in a model of
cerebral ischemia in preclinical study.9 LEV has been also reported
to be well tolerated and effective in SE refractory to BDZ.8 However,
there was little preclinical or clinical data concerning the outcomes
of LEV in comparison to DZP, and VPA in SE-induced neuronal
death. To address this relevant lack of information, we havevier Ltd. All rights reserved.
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VPA, and LEV alone, and the efﬁcacy of LEV as an add-on treatment
with DZP on the SE-induced neuronal death.
2. Experimental procedures
2.1. Experimental animals and chemicals
This study utilized the progeny of Sprague-Dawley (SD) rats
(male, 9–11 weeks old) obtained from Experimental Animal
Center, Hallym University, Chunchon, South Korea. The animals
were provided with a commercial diet and water ad libitum under
controlled temperature, humidity and lighting conditions
(22  2 8C 55  5% and a 12:12 light/dark cycle with lights).
Procedures involving animals and their care were conducted in
accord with our institutional guidelines that comply with NIH Guide
for the Care and Use of Laboratory Animals (National Institutes of
Health (NIH) Guide for the Care and Use of Laboratory Animals, NIH
Publications No. 80-23, 1996). In addition, we have made all efforts to
minimize the number of animals used and their suffering. All reagents
were obtained from Sigma (MO, USA), except as noted.
2.2. Seizure induction and drug treatments
Animals were given LiCl (Sigma–Aldrich Co., St. Louis, MO, USA;
3 mEq/kg i.p.) 24 h before the pilocarpine treatment. Animals were
i.p. treated with pilocarpine (Sigma–Aldrich Co., St. Louis, MO, USA;
30 mg/kg i.p.) 20 min after atropine methylbromide (Sigma–
Aldrich Co., St. Louis, MO, USA; 5 mg/kg i.p.) and were placed in
individual observation chambers where seizure activity was
scored according to the system of Racine.10 Animals that entered
SE typically did so within 20–30 min of the administration of
pilocarpine and exhibited continuous seizure activity between 2
and 5 on the Racine scale (including akinesia, facial automatisms,
limbic seizures consisting of forelimb clonus with rearing,
salivation, masticatory jaw movements, and falling).
One of the following drugs (n = 14 per group) was administered
2 h after onset of SE; (1) DZP (Valium, Hoffman Ia Roche, Neuilly
sur-Seine, France; 10 mg/kg i.p.), (2) LEV (UCB, Belgium, 50, 100,
and 150 mg/kg, i.p., respectively), (3) VPA (50, 100, and 150 mg/kg,
i.p., respectively), (4) DZP (10 mg/kg, i.p.) + LEV (50, 100, and
150 mg/kg, i.p., respectively), (5) DZP (10 mg/kg, i.p.) + VPA (50,
100, and 150 mg/kg, i.p., respectively), and (6) DZP (10 mg/kg,
i.p.) + oxiracetam (OXI, 50, 100, and 150 mg/kg, i.p., respectively).
The dosage of each drug was chosen based on its anticonvulsive
concentration to control seizure activity induced by SE in theFig. 1. The effect of each compound on behavioral seizure activity (within 30 min after 
inhibitory effect of behavioral seizure activity from each compound (n = 14 per group)preliminary study and our previous study.11 In addition, OXI was
chosen as a comparison drug for LEV, because OXI has the similar
chemical structures of LEV. Fig. 1 shows the effect of each
compound on behavioral seizure activity within 30 min after
injection and mortality.
2.3. Tissue processing
In our previous study, neuronal damage in the hippocampus
was noticeable at 3–4 days after SE.3 Therefore, we determined 4
days after SE as the best time point to evaluate neuronal damage
induced by SE.3 Animals (n = 5 per group) were perfused
transcardially with phosphate-buffered saline followed by 4%
paraformaldehyde in 0.1 M phosphate buffer (pH 7.4) under
urethane anesthesia (Sigma–Aldrich Co., St. Louis, MO, USA; 1.5 g/
kg, i.p.) for 20 min. The brains were removed, and postﬁxed in the
same ﬁxative for 4 h. The brain tissues were cryoprotected by
inﬁltration with 30% sucrose overnight. Thereafter, the entire
hippocampus was frozen and sectioned with a cryostat at 30 mm
and consecutive sections were placed in six-well plates containing
PBS. For stereological study, every sixth section in the series
throughout the entire hippocampus was used for evaluation of
neuronal damage.12
2.4. Fluoro-Jade B staining
Fluoro-Jade B (FJB) staining was used to identify degenerating
neurons. Brieﬂy, sections were rinsed in distilled water, and
mounted onto gelatin-coated slides and then dried on a slide
warmer. The slides were immersed in 100% ethanol for 3 min,
followed by 70% ethanol for 2 min and distilled water for 2 min.
The slides were then transferred to 0.06% potassium permanganate
for 15 min and gently agitated. After rinsing in distilled water for
2 min, the slides were incubated for 30 min in 0.001% FJB (Histo-
Chem Inc. Jefferson, AR, USA), freshly prepared by adding 20 ml of a
0.01% stock FJB solution to 180 ml of 0.1% acetic acid, with gentle
shaking in the dark. After rinsing for 1 min in each of three changes
of distilled water, the slides were dried, dehydrated in xylene and
coverslipped with DPX. For stereological study, every sixth section
in the series throughout the entire hippocampus was used (see
below).
2.5. Stereology
Hippocampal volumes (V) were estimated according to a
formula based on the modiﬁed Cavalieri method:injection) and mortality (until 4 days after injection). There is no differences of the
.
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delineated subﬁeld measured by AxioVision Rel. 4.8 software,
tnom is the nominal section thickness (of 30 mm in this study), and
ssf is the fraction of the sections sampled or section sampling
fraction (of 1/6 in this study). The subﬁeld areas were delineated
with a 2.5 objective lens. The volumes are reported as mm3.13 The
optical fractionator was used to estimate cell numbers. The optical
fractionator (a combination of performing counting with the
optical disector, with fractionator sampling) is a stereological
method based on a properly designed systematic random sampling
method that by deﬁnition yields unbiased estimates of population
number. The sampling procedure is accomplished by focusing
through the depth of the tissue (the optical disector height, h; of
15 mm in all cases for this study). The number of each cell type (C)
in each of the subregions is estimated as: C = SQ  t/h  1/
asf  1/ssf, where Q is the number of cells actually counted in the
disectors that fall within the sectional proﬁles of the subregionFig. 2. The effect of LEV on SE-induced neuronal death in comparison to DZP. (A–D) Repr
100 mg/kg; D, LEV 150 mg/kg. Panels 1, CA1 pyramidal cell layer; Panels 2, CA3 pyramid
neuronal damage induced by SE. Bar = 50 mm. (E) The quantitative analysis of neuron
*p < 0.05 (n = 5 per group).seen on the sampled sections, and asf is the area sampling fraction
calculated as the area of the counting frame of the dissector,
a(frame) (50 mm  50 mm in this study) and the area associated
with each x, y movement, grid (x, y step) (250 mm  250 mm in this
study) {asf = [a(frame)/a(x, y step)]}. FJB-positive cells were
counted with a 40 objective lens. All FJB-positive cells were
counted regardless the intensity of labeling. Therefore, the total
number of cells was corrected by multiplying with appropriate
correction factors (CF) representing the degree of shrinkage (or
swelling) compared with the non-SE animals. Cell counts were
performed by two different investigators who were blind to the
classiﬁcation of tissues.12
2.6. Volumetry for vasogenic edema
In our previous study, vasogenic edema and neuronal damage
in the PC were noticeable at 1 day and 3 days after SE,esentative photographs of FJB staining following SE. A, DZP; B, LEV 50 mg/kg; C, LEV
al cell layer; Panels 3, Dentate hilus. As compared to DZP, LEV treatment attenuates
al damage after SE (mean  S.D.). Signiﬁcant differences from DZP-treated animals,
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the best time point to evaluate the effect of test drugs on vasogenic
edema induced by SE. Three days after SE, animals (n = 5 per group)
were perfused by the same method described above. To measure
vasogenic edema lesion, sections were reacted for serum-proteins
using horse anti-rat IgG (Vector, USA) in PBS containing 0.3% Triton
X-100 and 2% normal goat serum overnight at room temperature.
After washing three times for 10 min with PBS, sections were
incubated in ABC complex (Vector, USA), diluted 1:200 in the same
solution. Between the incubations, the tissues were washed with
PBS three times for 10 min each. The sections were visualized with
3,30-diaminobenzidine (DAB) in 0.1 M Tris buffer and mounted on
the gelatin-coated slides. The immunoreaction was observed
under the Axioscope microscope (Carl Zeiss, Germany). Thereafter,
volume of vasogenic edema lesion (V) were estimated according
to a formula based on the modiﬁed Cavalieri method:
V = Sa  tnom  1/ssf, where a is area of the region of the
delineated subﬁeld measured by AxioVision Rel. 4.8 software,
tnom is the nominal section thickness (of 30 mm in this study), and
ssf is the fraction of the sections sampled or section sampling
fraction (of 1/6 in this study). The subﬁeld areas were delineated
with a 2.5 objective lens. The volumes are reported as mm3.13,14Fig. 3. The effect of VPA on SE-induced neuronal death in comparison to DZP. (A–D) Repre
100 mg/kg; D, VPA 150 mg/kg. Panels 1, CA1 pyramidal cell layer; Panels 2, CA3 pyramid
neuronal damage induced by SE. Bar = 50 mm. (E) The quantitative analysis of neuron
*p < 0.05 (n = 5 per group).2.7. Statistical analysis
All data obtained from the quantitative measurements were
analyzed using one-way ANOVA to determine statistical signiﬁ-
cance. Bonferroni’s test was used for post hoc comparisons. A p-
value below 0.05 was considered statistically signiﬁcant.2
3. Results
3.1. The effect of LEV alone on SE-induced neuronal death
In the DZP-treated group, the numbers of FJB positive
degenerative neurons per mm3 in CA1-, CA3 pyramidal cells,
and dentate hilar neurons were 24,318  1993, 13,182  2314, and
14,545  2443, respectively (Fig. 2A, E). In the LEV-50 mg/kg treated
group, the numbers of FJB positive degenerative neurons per mm3 in
CA1-, CA3 pyramidal cells, and dentate hilar neurons were
7341  983, 20,136  7069, and 9705  766, respectively (Fig. 2B,
E). These ﬁndings indicate that LEV-50 mg/kg treatment may
effectively reduce the SE-induced neuronal death in CA1 pyramidal
cells and dentate hilar neurons (not CA3 pyramidal cells) as compared
to DZP treatment (p < 0.05; Fig. 2B and E). LEV-100 mg/kg treatmentsentative photographs of FJB staining following SE. A, DZP; B, VPA 50 mg/kg; C, VPA
al cell layer; Panels 3, Dentate hilus. As compared to DZP, VPA treatment attenuates
al damage after SE (mean  S.D.). Signiﬁcant differences from DZP-treated animals,
Fig. 4. The effect of LEV as an add-on drug on SE-induced neuronal death in comparison to LEV alone. (A–F) Representative photographs of FJB staining following SE. A, LEV
50 mg/kg; B, LEV 50 mg/kg + DZP; C, LEV 100 mg/kg; D, LEV 100 mg/kg + DZP; E, LEV 150 mg/kg; F, LEV 150 mg/kg + DZP. Panels 1, CA1 pyramidal cell layer; Panels 2, CA3
pyramidal cell layer; Panels 3, Dentate hilus. As compared to LEV single treatment, LEV add-on treatment with DZP exacerbates neuronal damage induced by SE. Bar = 50 mm.
(G) The quantitative analysis of neuronal damage after SE (mean  S.D.). Signiﬁcant differences from the same dose of LEV-treated animals, *p < 0.05 (n = 5 per group).
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neurons per mm3 in CA1-, CA3 pyramidal cells, and dentate hilar
neurons to 2477  300, 7341  916, and 2523  717, respectively
(p < 0.05 vs. DZP, and LEV-50 mg/kg treated group, Fig. 2C, E).
LEV-150 mg/kg treatment showed the numbers of FJB positivedegenerative neurons per mm3 in CA1-, CA3 pyramdical cells, and
dentate hilar neurons as 2091  386, 2818  1286, and 1318  450,
respectively (Fig. 2D, E). Therefore, LEV-150 mg/kg treatment could
effectively reduce FJB positive degenerative neurons only in CA3
pyramidal cells (p < 0.05) as compared to LEV-100 mg/kg treatment.
Fig. 5. The effect of OXI as an add-on drug on SE-induced neuronal death. (A–C) Representative photographs of FJB staining following SE. A, OXI 50 mg/kg + DZP; B, OXI
100 mg/kg + DZP; C, OXI 150 mg/kg + DZP. Panels 1, CA1 pyramidal cell layer; Panels 2, CA3 pyramidal cell layer; Panels 3, Dentate hilus. Similar to LEV, OXI add-on treatment
with DZP exacerbates SE-neuronal damage. Bar = 50 mm. (D) The quantitative analysis of neuronal damage after SE (mean  S.D.). Signiﬁcant differences from OXI 50 mg/
kg + DZP-treated animals, *p < 0.05 (n = 5 per group).
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neuronal damage from SE.
3.2. The effect of VPA alone on SE-induced neuronal death
In the VPA-50 mg/kg treated group, the numbers of FJB
positive degenerative neurons per mm3 in CA1-, CA3 pyramidal
cells, and dentate hilar neurons were 18,333  3489,
15,758  3624, and 14,894  3248, respectively. These ﬁndings
indicate that VPA-50 mg/kg treatment may not be effective to
reduce the SE-induced neuronal death as compared to DZP
treatment (Fig. 3A, B and E). VPA-100 mg/kg treatment signiﬁcant-
ly reduced the numbers of FJB positive degenerative neurons per
mm3 in CA1-, CA3 pyramidal cells, and dentate hilar neurons to
12,625  2028, 12,068  2130, and 10,318  1897, respectively.These ﬁndings indicate that VPA-100 mg/kg treatment may
effectively reduce the SE-induced neuronal death in CA1 pyramidal
cells and dentate hilar neurons (not CA3 pyramidal cells) as
compared to DZP treatment (p < 0.05; Fig. 3A, C and E). VPA-
150 mg/kg treatment reduced the numbers of FJB positive
degenerative neurons per mm3 in CA1-, CA3 pyramidal cells,
and dentate hilar neurons as 12,432  2879, 9205  2896, and
8273  1068, respectively. Therefore, VPA-150 mg/kg treatment
showed the similar effect on SE-induced neuronal death, as
compared to VPA-100 mg/kg. Furthermore, the number of FJB
positive neurons in every VAP treated groups was higher than that
in the same-dosage LEV treated groups (p < 0.05; Fig. 3A, D and E).
These ﬁndings indicate that LEV may be more effective to prevent
neuronal death from SE insults than that of the same dosage
of VPA.
Fig. 6. The effect of VPA as an add-on drug on SE-induced neuronal death in comparison to VPA alone. (A–F) Representative photographs of FJB staining following SE. A, VPA
50 mg/kg; B, VPA 50 mg/kg + DZP; C, VPA 100 mg/kg; D, VPA 100 mg/kg + DZP; E, VPA 150 mg/kg; F, VPA 150 mg/kg + DZP. Panels 1, CA1 pyramidal cell layer; Panels 2, CA3
pyramidal cell layer; Panels 3, Dentate hilus. As compared to VPA single treatment, VPA add-on treatment with DZP alleviates neuronal damage induced by SE. Bar = 50 mm.
(G) The quantitative analysis of neuronal damage after SE (mean  S.D.). Signiﬁcant differences from the same dose of VPA-treated animals, *p < 0.05 (n = 5 per group).
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In the DZP + LEV-50 mg/kg treated group, the numbers of FJB
positive degenerative neurons per mm3 in CA1-, CA3 pyramidal
cells, and dentate hilar neurons were 33,227  4023,30,000  10,391, and 12,773  5510, respectively. These results
indicated that co-treatment of DZP + LEV-50 mg/kg might exacerbate
SE-induced neuronal damage in CA1 pyramidal cells as compared to
DZP alone (p < 0.05; Fig. 4B, G), and LEV-50 mg/kg alone (p < 0.05;
Fig. 4A, G). In addition, co-treatment of DZP + LEV-100 mg/kg groups
Fig. 7. Effect of test drugs on SE-induced vasogenic edema and neuronal damage in the PC. (A) Representative photographs of serum-protein extravasation in the PC after SE.
Bars = 400 mm. (B) Representative photographs of FJB staining in the PC after SE. Bars = 50 mm. (C–H) Quantitative analyses of serum-protein extravasation and neuronal
damage in the PC after SE (mean  S.D.). There is no protective effect of each test drug (alone or as add-on) from SE-induced vasogenic edema formation compared to DZP (n = 5 per
group).
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CA1-, CA3 pyramidal cells, and dentate hilar neurons were
15,068  4326, 18,364  9663, and 15,864  1132, respectively
(Fig. 4D, G). In the DZP + LEV-150 mg/kg treated group, the numbers
of FJB positive degenerative neurons per mm3 in CA1-, CA3 pyramidalcells, and dentate hilar neurons were 13,091  2097, 17,212  1627, and
11,091  1969, respectively (Fig. 4F, G). These results revealed that co-
treatment of DZP + LEV might aggravate SE-induced neuronal damage as
compared to LEV alone (p < 0.05; Fig. 4G). In other words, DZP co-
treatment could alleviate neuroprotective effect of LEV against SE.
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In the DZP + OXI-50 mg/kg treated group, the numbers of FJB
positive degenerative neurons per mm3 in CA1-, CA3 pyramdical
cells, and dentate hilar neurons were 1523  422, 2818  1222, and
1682  558, respectively (Fig. 5A, D). In addition, co-treatment of
DZP + OXI-100 mg/kg groups showed the numbers of FJB positive
degenerative neurons per mm3 in CA1-, CA3 pyramidal cells, and
dentate hilar neurons were 1205  172, 2121  367, and 2394  845,
respectively (Fig. 5B, D). Unlike LEV, these results indicated that co-
treatment of DZP + OXI-50 mg/kg, and +OXI-100 mg/kg might
alleviate SE-induced neuronal damage as compared to DZP alone
(p < 0.05; Fig. 5D). In addition, these neuroprotective effects of OXI
did not show dose-dependent manners. However, DZP + OXI-150 mg/
kg treated group showed the increase in the degree of SE-induced
neuronal death, as compared to DZP treated group; the numbers of
FJB positive degenerative neurons per mm3 in CA1-, CA3 pyramdical
cells, and dentate hilar neurons were 25,576  1863, 17,803  4693,
and 12,682  2136, respectively (Fig. 5C, D). These results indicate
that co-treatment of LEV-like drugs with DZP may alleviate or
aggravate SE-induced neuronal damage dependent on their dosages.
3.5. The effect of VPA as an add-on drug on SE-induced neuronal death
In the DZP + VPA-50 mg/kg treated group, the numbers of FJB
positive degenerative neurons per mm3 in CA1-, CA3 pyramidal
cells, and dentate hilar neurons were 14,258  2450, 10,530 
3683, and 11,727  1473, respectively. These results indicated that
co-treatment of DZP + VPA-50 mg/kg might alleviate SE-induced
neuronal damage in CA1-, and CA3 pyramidal cells, as compared to
VPA alone (p < 0.05; Fig. 2B, C), and VPA-50 mg/kg alone (p < 0.05;
Fig. 6A, B and G). Co-treatment of DZP + VPA-100 mg/kg groups
showed the numbers of FJB positive degenerative neurons per mm3 in
CA1-, CA3 pyramidal cells, and dentate hilar neurons were
10,841  1024, 9818  3522, and 6432  1768, respectively. In the
DZP + VPA-150 mg/kg treated group, the numbers of FJB positive
degenerative neurons per mm3 in CA1-, CA3 pyramidal cells, and
dentate hilar neurons were 12,745  3161, 10,873  1287, and
7473  2429, respectively. These results revealed that co-treatment
of DZP + VPA-100 mg/kg, and +VPA-150 mg/kg might restrictedly
reduce SE-induced neuronal damage (in dentate hilar neurons) as
compared to VPA alone (p < 0.05; Fig. 6C–G).
3.6. The effects of test drugs on SE-induced vasogenic edema
In the DZP-treated  group, volume of vasogenic edema was
19.4  2.3 mm3. In the LEV treated groups (50, 100, 150 mg/kg),
volumes of vasogenic edema were 21.3  3.6, 22.4  4.1, 19.3 
3.4 mm3, respectively. In the VPA treated groups (50, 100, 150 mg/
kg), volumes of vasogenic edema were 18.9  5.8, 21.3  3.7,
22.3  5.1 mm3, respectively. In the LEV (50, 100, 150 mg/kg) + DZP
treated groups, volumes of vasogenic edema were 19.6  4.8, 18.9  5.1,
21.8  4.8 mm3, respectively. In the OXI (50, 100, 150 mg/kg) + DZP
treated groups, volumes of vasogenic edema were 21.0  5.1, 19.8  4.8,
20.1  3.8 mm3, respectively. In the VPA (50, 100, 150 mg/kg) + DZP
treated groups, volumes of vasogenic edema were 19.7  4.3, 21.2  3.7,
20.7  3.8 mm3, respectively. Furthermore, the numbers of FJB positive
degenerative neurons in PC neurons were not different from each group.
Therefore, there was no protective effect of each test drug (alone or as
add-on) from SE-induced vasogenic edema formation and nueornal
damage in the PC compared to DZP (Fig. 7).
4. Discussion
The major ﬁndings of the present study are that LEV has
neuroprotective effect from SE-induced neuronal death, but notvasogenic edema, as a single treatment or an add-on drug. LEV has a
wide spectrum of action and a favorable pharmacokinetic proﬁle.
The mechanism of its action is distinct from that of classic AEDs and
unrelated to known mechanisms of neurotransmission but seems to
involve the synaptic vesicle protein 2A.15 In addition, LEV inhibits
HVA-Ca2 channels (N-type), reverses the inhibition of negative
allosteric modulators such as zinc and b-carbolines of g-aminobu-
tyric acid (GABA)- and glycine-gated currents, and reduces the
calcium release from intraneuronal stores.15 Furthermore, neuro-
protective effects of LEV have been described in animal models.16
In the present study, LEV (50 mg/kg) was signiﬁcantly
effective to protect neuronal damage from SE in comparison to
DZP and VPA. However, it is noticeable that LEV as an add-on drug
with DZP could not alleviate SE-induced neuronal damage as
compared to LEV alone, and showed the similar effect of DZP alone.
VPA (100 mg/kg) was signiﬁcantly effective to protect neuronal
damage from SE, as compared to DZP. In contrast to LEV, VPA (50
and 100 mg/kg) as an add-on drug with DZP signiﬁcantly reduced
SE-induced neuronal damage as compared to DZP alone, and
showed the similar effect of VPA (150 mg/kg) alone. These ﬁndings
indicate that, unlike VPA, LEV may negatively interact with DZP.
This hypothesis is supported by our other study using OXI, a
chemical analog of LEV. Similar to LEV, co-treatment of OXI
(150 mg/kg) and DZP exacerbated SE-induced neuronal death as
compared to OXI alone. Based on these ﬁndings, it is likely that
analogs of LEV including OXI and piracetam may interact with BDZ
family. Therefore, our ﬁndings suggest that LEV may be more
effective to prevent SE-induced neuronal death as a ﬁrst line drug
than as a second line therapy after BDZ treatment, and that LEV as
an add-on drug with BDZ may not provide any additional beneﬁt to
outcome of SE.
One the other hand, the efﬁcacy of LEV and VPA in SE-induced
neuronal death showed regional speciﬁc manners (CA1 pyramidal
cells > dentate hilar cell > CA3 pyramidal cells). These discrepan-
cies would be resulted from differential susceptibility of hippo-
campal neurons to a kind of insults. Although dentate granule cells
are remarkably resistant to neuronal damage caused by most
insults, including hypoxia/ischemia and seizures, dentate hilar
neurons are vulnerable to seizure-induced damage.3 CA3 pyrami-
dal neurons are extremely sensitive to seizure-induced or trauma-
induced damage, and CA1 pyramidal neurons are susceptible to
both hypoxia/ischemia- and seizure-induced neurodegenera-
tion.17 Following DZP treatment, electroencephalogram exhibits
the frequent occurrence of interictal spikes and occasionally
sustained ictal discharges until 2 days after SE without behavioral
seizure activity.18 Therefore, it would not be excluded that the
distinct effect of each compound on long-lasting electroencepha-
lographic seizure activity may result in regional speciﬁc patterns of
SE-induced neuronal death. Further studies are needed to elucidate
the role of AEDs in regional speciﬁc neuronal injuries.
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